NK cell expansion after primary multimodal treatment to predict progression free survival in inoperable stage III NSCLC. Management and treatment of patients with stage III unresected NSCLC at UPMC: A ...

In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing. He will review the NSCLC ...

The estimated glomerular filtration rate (eGFR) is a blood test to assess kidney function. The formula for calculating eGFR takes the patient’s body size, age, and sex into account to predict how well ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer. The targeted therapy osimertinib (Tagrisso, AstraZeneca) improved progression-free survival (PFS) by ...

Of the 499,997 people with complete data, 93,406 (18.7%) had at least one eGFR < 60 ml/min/1.73 m 2. Only a small number of those (6044, 6.5%) had no further eGFR testing (Figure 2). We identified ...

Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved testing strategies and healthcare access.

Please provide your email address to receive an email when new articles are posted on . 32.2% of Medicare fee-for-service beneficiaries received yearly eGFR and urinary albumin-creatinine ratio ...